- Legend Biotech recently reported record quarterly sales and profitability milestones for its CARVYKTI multiple myeloma therapy, alongside expanded global access and the past removal of FDA REMS restrictions that had limited how patients were monitored and allowed to drive.
- These updates highlight how CARVYKTI has become one of the most widely used CAR-T treatments, supported by long-term survival data, growing manufacturing capacity and broader international launches that together could shape Legend’s future growth profile.
- Next, we’ll examine how CARVYKTI’s record sales and improving safety profile may influence Legend Biotech’s longer-term investment narrative.
Outshine the giants: these 21 early-stage AI stocks could fund your retirement.
Legend Biotech Investment Narrative Recap
To own Legend Biotech, you have to believe CARVYKTI can sustain leadership in multiple myeloma while the rest of the pipeline gradually reduces single-product dependence. The latest record sales, improving safety profile and expanded access strengthen the near term catalyst around CARVYKTI adoption, but they do not fully resolve the central risk that setbacks in this one therapy could still weigh heavily on revenue and earnings.
Among recent developments, the FDA’s removal of REMS restrictions for CARVYKTI looks especially important. Easing monitoring and driving limits directly supports broader real world use, which matters for monetizing Legend’s growing manufacturing capacity and for near term milestones tied to earlier line adoption and international launches, even as competition and pricing pressure remain key watchpoints for the story.
Yet, despite these positive headlines, investors should also be aware of how concentrated Legend’s fortunes remain in a single therapy and how quickly the competitive multiple myeloma treatment field is evolving...
Read the full narrative on Legend Biotech (it's free!)
Legend Biotech's narrative projects $2.1 billion revenue and $499.4 million earnings by 2029.
Uncover how Legend Biotech's forecasts yield a $57.22 fair value, a 199% upside to its current price.
Exploring Other Perspectives
Some analysts were already far more optimistic, assuming revenue could reach about US$3.0 billion and earnings around US$930.5 million by 2028, so this new CARVYKTI momentum may either reinforce that bullish view or prompt a rethink if risks like partnership limits on margins and pricing pressure start to matter more than expected.
Explore 5 other fair value estimates on Legend Biotech - why the stock might be worth just $21.00!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Legend Biotech research is our analysis highlighting 2 key rewards that could impact your investment decision.
- Our free Legend Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Legend Biotech's overall financial health at a glance.
Ready For A Different Approach?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Find 58 companies with promising cash flow potential yet trading below their fair value.
- We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com